{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000089","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.857174+00:00","generated_at":"2026-05-28T07:43:14.946116+00:00","sec_items":["2.02","8.01","2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cassava cuts workforce 33% after Phase 3 miss; REFOCUS-ALZ results due Q1/Q2 2025","bullets":["Workforce reduction of 10 employees (33%) with ~$0.4M severance costs in Q1 2025.","Cash and cash equivalents ~$128.6M as of Dec 31, 2024 (unaudited).","Topline data from Phase 3 REFOCUS-ALZ study expected late Q1/early Q2 2025.","Halting planned biomarker analysis of additional plasma samples from prior Phase 2 studies.","RETHINK-ALZ study did not meet co-primary endpoints; REFOCUS-ALZ and OLE study discontinued."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000089","json":"https://secwatch.observer/filing/0001171843-25-000089.json","markdown":"https://secwatch.observer/filing/0001171843-25-000089.md","text":"https://secwatch.observer/filing/0001171843-25-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/0001171843-25-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/f8k_010725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T07:43:14.946116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9995eff96a80efae30b6a2ec0228e6925f6b30e4","claim":"FILANA THERAPEUTICS, INC. announced a restructuring with charges of approximately $0.4 million (10 employees, a reduction of 33%).","evidence_excerpt":"The Company estimates that it will incur approximately $0.4 million of one-time costs in connection with the Workforce Reduction, primarily related to severance payments.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325000089/0001171843-25-000089-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.4 million"},{"label":"Headcount","value":"10 employees, a reduction of 33%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}